On May 26, 2022 Alchemab Therapeutics, a biotechnology company focused on the discovery and development of naturally-occurring protective antibodies and immune repertoire-based patient stratification tools, reported that Young T. Kwon, PhD, Alchemab’s Chief Financial and Operating Officer, has succeeded Douglas A. Treco, PhD as Chief Executive Officer and member of the Board, who resigned for personal reasons (Press release, Alchemab Therapeutics, MAY 26, 2022, View Source [SID1234615065]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Houman Ashrafian, Chairman of the Board said, "Doug was instrumental to our successful Series A financing and has made significant contributions to Alchemab. He led us in advancing our novel platform and our lead programs in neurodegeneration and cancer, and has helped build out an extremely talented team and established a solid operational foundation, including new operations in the U.S. We are extremely fortunate that he has been a part of Alchemab during this period of rapid growth and scientific progress."

"We are delighted that Young will lead our Company and join our Board," Dr. Ashrafian continued. "He has established himself as an outstanding leader and we are thrilled that he will be driving the Company forward during this exciting phase of growth. In addition to building transformative biotech companies, Young’s track record working with and developing talented teams will build on and shape Alchemab’s diverse, ambitious and unique culture. As the Company continues to grow its footprint in the U.S. and the U.K., we look forward to working with Young to advance our novel programs to the clinic and build out our highly differentiated platform."

"I am excited by Alchemab’s potential," said Dr. Kwon, "Over the last six months I have seen how combining experienced drug discovery capabilities with the latest computational approaches pave a new era in therapeutics discovery. I am grateful to Doug for his support and guidance and I look forward to the challenge of building upon the outstanding foundations that he has established."

Dr. Kwon has served as Alchemab’s Chief Financial and Operating Officer since November 2021. Dr. Kwon previously served as Chief Financial and Business Officer of Momenta Pharmaceuticals until its acquisition by Johnson & Johnson in October 2020. Prior to Momenta, Dr. Kwon was a business development professional at Biogen and worked at the venture capital firm Advanced Technology Ventures, investing in early-stage biotech and medical device companies. Dr. Kwon received a B.S. in biology from Massachusetts Institute of Technology and a Ph.D. in Biological Chemistry and Molecular Pharmacology from Harvard University.

On May 26, 2022 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that members of its management team will participate in two upcoming investor conferences (Press release, Syndax, MAY 26, 2022, View Source [SID1234615064]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A virtual fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit at 12:30 p.m. ET on Thursday, June 2, 2022.
A fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference at 6:20 p.m. ET/ 3:20 p.m. PT on Tuesday, June 14, 2022 in Rancho Palos Verdes, CA.
A live webcast of the fireside chats can be accessed from the Investor section of the Company’s website at www.syndax.com, where a replay of the events will also be available for a limited time.

On May 26, 2022 Akili Interactive ("Akili"), a leading digital medicine company pioneering the development of cognitive treatments through game-changing technologies, and Roblox (NYSE: RBLX), a global platform bringing millions of people together through shared experiences, reported a collaboration that connects patients’ medical treatments to their favorite virtual worlds (Press release, PureTech Health, MAY 26, 2022, View Source [SID1234615063]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Roblox brings together tens of millions of people every day to connect, create, and express themselves, and we’re proud to be working with Akili to leverage that passion and enjoyment in connection with their first-in-class digital treatment," said Craig Donato, Chief Business Officer of Roblox. "Akili has captured our imagination with its prescription treatment for children with ADHD delivered through an action video game experience and shares our vision and enthusiasm for what’s possible through interactive, digital experiences. We’re proud to help them as they lead the effort to realize new potential in the field of medicine."

Through this partnership, Akili and Roblox are introducing new ways for medicine to fit into patients’ lives. Initially, the companies will establish an exclusive Roblox rewards exchange tied to Akili’s EndeavorRx treatment (see full indication below). The companies are exploring additional novel approaches and opportunities to engage Akili patients through Roblox integrations.

"We are committed to improving the world’s cognitive health through treatments that engage and wow patients," said Eddie Martucci, CEO and Co-Founder of Akili Interactive. "Our FDA-cleared video game treatment demonstrates that medicine can be enjoyable, and that is only the beginning. Akili’s long-term vision aims to integrate digital medicine into patients’ daily lives in ways never before seen or experienced. Roblox has changed how millions learn, work, connect and play, and we are excited to work together to further push the boundaries of our industries and continue to redefine the experience of medicine."

Akili and Roblox are natural partners. Akili has challenged traditional perceptions of medicine and created EndeavorRx, the first and only prescription video game treatment for children with ADHD, cleared by the U.S. Food and Drug Administration (FDA). With more than 55 million people worldwide coming together on Roblox every day, Roblox is powering a platform for immersive, 3D shared experiences. Together, they have the ability to reimagine the patient experience.

EndeavorRx Indication and Overview

EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8 to 12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child’s medication. EndeavorRx associated adverse events in clinical trials included frustration (6.1%), headache (1.3%), dizziness (0.6%), emotional reaction (0.4%), nausea (0.4%), and aggression (0.2%). No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child’s health care provider.

On May 26, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in three upcoming investor conferences (Press release, Kura Oncology, MAY 26, 2022, View Source [SID1234615062]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A virtual fireside chat at Cowen’s 3rd Annual Oncology Innovation Summit at 3:30 p.m. ET / 12:30 p.m. PT on June 2, 2022;

A fireside chat at the Jefferies Healthcare Conference in New York at 10:30 a.m. ET / 7:30 a.m. PT on June 8, 2022; and

A fireside chat at the JMP Securities Life Sciences Conference in New York at 2:30 p.m. ET / 11:30 a.m. PT on June 16, 2022.
Audio webcasts will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following each event.

On May 26, 2022 FibroGen, Inc. (NASDAQ: FGEN) reported that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference on Thursday, June 9 at 1:30pm EDT (Press release, FibroGen, MAY 26, 2022, View Source [SID1234615061]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the event will be available on the "Events & Presentations" section of the FibroGen Investors webpage at www.fibrogen.com. A replay will be available for approximately 30 days.